4 "Strong Buy" Stocks for a Fear-Driven Market

NYSE: ABBV | AbbVie Inc.  News, Ratings, and Charts

ABBV – Even though the inflation declined slightly from the 40-year high in July, it stayed elevated. Therefore, the Fed could maintain its hawkish stance on tightening monetary policy, which will drive market volatility. Amid this fear-driven market, we think it could be prudent to invest in fundamentally sound stocks AbbVie (ABBV), Merck & Co. (MRK), Commvault System (CVLT), and The Hackett Group (HCKT). They have rated a Strong Buy in our proprietary rating system. Read on to learn more….

Inflation has been a major concern for the market this year, resulting in a massive stock market sell-off. The year’s first half ended up being the worst for the stock market in 50 years. High consumer demand and supply constraints have driven prices higher.

While the recently released CPI data shows a slight decline in inflation from the 40-year high level, it remained elevated. Food and rent continued to march higher. Therefore, the Fed might consider continuing its aggressive interest rate hikes given the red-hot job market.

As the fears of economic contraction are expected to keep the market volatile, it could be wise to invest in quality stocks AbbVie Inc. (ABBV), Merck & Co. Inc. (MRK), and Commvault System Inc. (CVLT), and The Hackett Group Inc. (HCKT). These stocks are rated Strong Buy in our proprietary POWR Ratings system.

AbbVie Inc. (ABBV)

ABBV is a biopharmaceutical research company. The company is involved in the research, development, manufacturing, commercialization, and sale of medicines and therapies. From AbbVie-owned distribution centers and public warehouses, the company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, and independent retailers worldwide.

This month, Sosei Group Corporation and ABBV, a global biopharmaceutical company focused on research, have announced a new drug discovery collaboration and option-to-license agreement to discover, develop, and commercialize small molecules that modulate novel G protein-coupled receptor (GPCR) targets linked to neurological disease. Sosei Heptares’ StaR technology and structure-based drug design (SBDD) platform will be used in the new agreement.

During the second quarter ended June 30, 2021, ABBV’s worldwide net revenue increased 4.5% year-over-year to $14.58 billion. Its adjusted EPS increased 11.2% year-over-year to $3.37. In addition, its gross margin came in at 71.4%.

ABBV’s revenue is expected to increase 5.2% year-over-year to $59.03 billion. In addition, its EPS is expected to grow 17.3% in the current year and 26.9% in the current quarter ending September 2022. The stock has gained 22.9% over the past year.

ABBV’s POWR Ratings reflect this promising outlook. The company has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. The POWR Ratings assess stocks by 118 different factors, each with its own weighting.

ABBV has an A grade for Quality and a B for Growth and Value. Within the Medical – Pharmaceuticals industry, it is ranked #9 of 173 stocks. To see additional POWR Ratings for Momentum, Stability, and Sentiment for ABBV, click here.

Merck & Co. Inc. (MRK)

MRK, Inc. is a global healthcare company. It operates in two segments: Pharmaceutical and Animal Health. The company has collaborations with AstraZeneca PLC (AZN), Bayer AG (BAYRY), Eisai Co. Ltd. (ESALY), Ridgeback Biotherapeutics, and Gilead Sciences, Inc. (GILD) to develop and commercialize long-acting HIV treatments.

This month, AstraZeneca and MRK announced that the European Commission (EC) had approved LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations (gBRCAm) and HER2-negative high-risk early breast cancer who have previously received neoadjuvant or adjuvant chemotherapy.

The European Commission approved LYNPARZA in this setting based on the results of the Phase 3 OlympiA trial and follows the European Medicines Agency’s Committee for Medicinal Products for Human Use’s recommendation.

MRK sales increased 27.9% year-over-year to $14.59 billion in the second quarter ended June 30, 2021. Its net income grew 155.3% year-over-year to $3.94 billion. Its EPS increased 154.1% from the prior-year quarter to $1.55.

The stock has gained 18.9% over the past year and 16.8% year-to-date.

Analysts expect MRK revenue to increase 20.5% year-over-year to $58.7 billion in fiscal 2022. Its EPS is expected to increase 22.4% from the prior-year quarter to $7.37. Over the past year, the stock has gained 155.8%. In addition, the stock has returned 124.5% so far this year.

MRK’s strong fundamentals are reflected in its POWR Ratings. The stock has an overall rating of A, which equates to a Strong Buy in our POWR Ratings system. MRK also has a B grade for Value and Quality. The stock is ranked #8 in the Medical – Pharmaceuticals industry.

Beyond the POWR Ratings grades I have just highlighted, you can see MRK ratings for Stability, Momentum, Sentiment, and Growth.

Commvault System Inc. (CVLT)

CVLT provides data protection and information management software applications, as well as related services, in the United States and internationally. It serves customers in various industries, including banking, insurance, financial services, government, healthcare, pharmaceuticals, medical services, technology, legal, manufacturing, utilities, and energy.

In June, CVLT expanded its strategic partnership with Oracle to include Metallic DMaaS on Oracle Cloud. Metallic’s industry-leading services will be available on Oracle Cloud Infrastructure (OCI) in all commercial OCI regions worldwide as part of Commvault’s multi-cloud strategy.

For the first quarter ended June 30, 2022, CVLT’s total revenue increased 7.9% year-over-year to $197.98 million. Its operating income came in at $7.44 million. The company’s net income came in at $3.51 million, while its EPS amounted to $0.08.

CVLT’s EPS is expected to increase 3.2% year-over-year to $2.59 in fiscal 2023. In addition, analysts expect its revenue to grow 5% to $807.87 million in the current fiscal year.

CVLT’s POWR Ratings reflect this promising outlook. The company has an overall rating of A, which translates to a Strong Buy in our proprietary rating system. JILL also has an A grade for Quality and a B for Growth and Value.

Within the Software Application industry, it is ranked #4 of 153 stocks. Click here to see additional POWR Ratings for Momentum, Sentiment, and Stability for CVLT.

The Hackett Group Inc. (HCKT)

The Hackett Group, Inc. is an intellectual property-based strategic consulting firm. Benchmarking, executive advisory, business transformation, and cloud enterprise application implementation are among the services offered by the company.

HCKT’s total revenue increased 3.7% year-over-year to $75.92 million in the second quarter ended July 1, 2022. Its cash and cash equivalents surged 34.7% for the three months ended July 1 to $61.68 million. Its adjusted EPS amounted to $0.38.

Its shares have gained 6.3% over the past month and 22.2% over the past year.

It is no surprise that HCKT has an overall A rating, which equates to Strong Buy in our POWR Ratings system. The stock also has an A grade for Quality and a B for Value and Stability. In the A-rated Outsourcing – Tech Services industry, it is ranked #1 of 10 stocks.

In addition to the POWR Ratings grades I have just highlighted, you can see HCKT ratings for Momentum, Growth, and Sentiment.


ABBV shares were trading at $140.94 per share on Wednesday afternoon, up $0.69 (+0.49%). Year-to-date, ABBV has gained 7.06%, versus a -10.97% rise in the benchmark S&P 500 index during the same period.


About the Author: Pragya Pandey


Pragya is an equity research analyst and financial journalist with a passion for investing. In college she majored in finance and is currently pursuing the CFA program and is a Level II candidate. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ABBVGet RatingGet RatingGet Rating
MRKGet RatingGet RatingGet Rating
CVLTGet RatingGet RatingGet Rating
HCKTGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


:  |  News, Ratings, and Charts

Bears Back in Charge...What Happens Next?

A month ago the bulls were claiming victory as they created a charge back over 4,000 for the S&P 500 (SPY). Since then that false narrative has been peeled away and investors are more honestly looking at the bleak outlook formed by high inflation and a hawkish Fed. That explains why we are back retesting the June lows. Now we have to ponder what comes next and how to trade our way to profits. Read on below for the full story...

:  |  News, Ratings, and Charts

2 Warren Buffett Stocks to Buy and Never Sell

Warren Buffett’s long-term value investing strategy serves as a guide for investors to ensure high returns. With the market volatility becoming more severe after the Fed’s recent interest rate hike, Buffett’s top holdings could be ideal investments for long-term investors. To that end, buying and holding Johnson & Johnson (JNJ) and United Parcel Service (UPS) could be wise. Continue reading…

:  |  News, Ratings, and Charts

3 Stocks That’ll Help You Score Big No Matter What Happens Next

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns despite market uncertainties, could be ideal buys now. Keep reading…

:  |  News, Ratings, and Charts

The Most Sought-After Tech Stock to Buy Right Now

Shares of Microsoft (MSFT) have shed more than 25% year-to-date, with the rising interest rates causing a massive tech sell-off. However, the current low price level allows long-term investors to take a position in the stock to benefit from its solid growth prospects. The company has guided double-digit growth for fiscal 2023. Moreover, MSFT has been increasingly paying dividends, which should help generate a steady income stream. Read more…

:  |  News, Ratings, and Charts

3 Stocks That’ll Help You Score Big No Matter What Happens Next

The Fed launched another 75-basis-point rate hike this week and signaled it would keep increasing rates until inflation is under control. The consecutive rate hikes are raising recession concerns. We think fundamentally solid stocks Bristol-Myers (BMY), AT&T (T), and Gilead Sciences (GILD), which have the potential to deliver steady returns despite market uncertainties, could be ideal buys now. Keep reading…

Read More Stories

More AbbVie Inc. (ABBV) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ABBV News